Neurology News

For individuals with anti-coagulation-associated intracerebral hemorrhage, a door-to-treatment time of 60 minutes or fewer was associated with decreased mortality and discharge to hospice care, according to research from JAMA Neurology.

Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.

A New York-based biopharmaceutical company has received a grant from Cure Parkinson’s to initiate a phase 2 clinical trial investigating dapansutrile, an oral small molecule, as a disease-modifying therapy for Parkinson’s disease.

Individuals with mania who were admitted to an acute care psychiatric unit saw greater sleep improvement than patients with major depressive disorder, according to a study.

RetinalGeniX Technologies has been granted a patent for its System and Method for Visualization of Ocular Anatomy, designed to aid in diagnosis of ocular and systemic diseases, according to a company press release.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses therapies in the pipeline that are working to target the cause of Huntington's disease.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses valbenazine, a recent approval in Huntington's disease care.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses risk factors that can be addressed early in Huntington's disease treatment, such as smoking and excessive alcohol intake.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, emphasizes the need for Huntington's disease awareness among providers and the general public.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses the unmet needs among patients with Huntington's disease and the clinicians who treat them.